|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Velcade inj[萬科 注射劑] information |
|
|
|
製造商 |
Janssen-Cilag |
|
代理/經銷商 |
Janssen-Cilag |
|
成份 |
Bortezomib |
|
適應症 |
In combination with melphalan & prednisolone for 1st line treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant. Treatment of multiple myeloma & mantle cell lymphoma patients who have received at least 1 prior therapy. |
|
用量 |
Adult 1.3 mg/m2 twice weekly for 2 weeks (days 1, 4, 8 & 11) followed by a 10-day rest period (days 12-21). Treatment cycle: 3 weeks. At least 72 hr should elapse between consecutive doses. Responding patients may receive up to 8 cycles of therapy. |
|
過量 |
View Velcade[萬科] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
[Click for Velcade[萬科] detailed prescribing infomation] |
|
注意事項 |
Peripheral neuropathy may develop or worsen; monitor patients for symptoms. History of syncope; patients taking drugs associated with hypotension; dehydrated patients. CHF may develop or exacerbate; monitor patients with risk factors for, or existing heart disease. Monitor CBC, platelet counts. Patients at risk of tumor lysis syndrome. Hepatic impairment. CrCl ≤13 mL/min & patients on hemodialysis. Pregnancy & lactation. |
|
不良反應 |
Fatigue, malaise & weakness, nausea, diarrhea, decreased appetite (including anorexia), constipation, thrombocytopenia, peripheral neuropathy (including peripheral sensory neuropathy & aggravated peripheral neuropathy), pyrexia, vomiting, anemia, neutropenia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Cytochrome P450 3A4 inhibitors or inducers. Oral antidiabetic agents. Drugs associated with peripheral neuropathy (e.g. amiodarone, antivirals, INH, nitrofurantoin or statins) or with a decrease in BP.
View more drug interactions with Velcade[萬科] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Velcade[萬科] detailed prescribing infomation |
|
儲存 |
View Velcade[萬科] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Velcade[萬科] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Velcade[萬科] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Velcade 注射劑 |
|
Velcade 3.5 mg x 10 mL x 1's |
|
|
|
Manufacturer: |
Janssen-Cilag |
|
Distributor: |
Janssen-Cilag |
|
|
|
|
|
